[go: up one dir, main page]

PE20140792A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
PE20140792A1
PE20140792A1 PE2013001327A PE2013001327A PE20140792A1 PE 20140792 A1 PE20140792 A1 PE 20140792A1 PE 2013001327 A PE2013001327 A PE 2013001327A PE 2013001327 A PE2013001327 A PE 2013001327A PE 20140792 A1 PE20140792 A1 PE 20140792A1
Authority
PE
Peru
Prior art keywords
composition
quinolin
halogen
phenyl
methyl
Prior art date
Application number
PE2013001327A
Other languages
English (en)
Inventor
Yu Cao
Wolfgang Hackl
Ping Li
Shoufeng Li
Tahseen Mirza
Hartmut Zehender
Jiahao Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45346568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140792(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20140792A1 publication Critical patent/PE20140792A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN COMPUESTO DE FORMULA (I), DONDE R1 ES NAFTILO, FENILO, ENTRE OTROS; R2 ES O O S; R3 ES ALQUILO C1-C7; R4 ES PIRIDILO, HALOGENO, CIANO, ENTRE OTROS; R5 ES H O HALOGENO; n ES 0 O 1; R6 ES OXIDO; R7 ES H O AMINO, b) UN TENSOACTIVO NO IONICO QUE ES LA VITAMINA E TPGS EN UNA CANTIDAD DE 15% A 80% EN PESO DE LA COMPOSICION, c) UN AGENTE MEJORADOR DE DISOLUCION SELECCIONADO DE POLIETILENGLICOL, POLI-OXIDO DE ETILENO Y COMBINACIONES DE LOS MISMOS. ES COMPUESTO PREFERIDO DE FORMULA (I) EL 2-METIL-2-[4-(3-METIL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-1-IL)-FENIL]-PROPIONITRILO O SU SAL DE MONOSILATO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS
PE2013001327A 2010-12-03 2011-12-01 Composiciones farmaceuticas PE20140792A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41953810P 2010-12-03 2010-12-03
US201161436324P 2011-01-26 2011-01-26

Publications (1)

Publication Number Publication Date
PE20140792A1 true PE20140792A1 (es) 2014-07-09

Family

ID=45346568

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001327A PE20140792A1 (es) 2010-12-03 2011-12-01 Composiciones farmaceuticas

Country Status (22)

Country Link
US (1) US20130245061A1 (es)
EP (1) EP2645999A2 (es)
JP (1) JP2013544845A (es)
KR (1) KR20140010009A (es)
CN (1) CN103237544A (es)
AR (1) AR084067A1 (es)
AU (1) AU2011336478A1 (es)
CA (1) CA2817618A1 (es)
CL (1) CL2013001557A1 (es)
CO (1) CO6801722A2 (es)
EC (1) ECSP13012654A (es)
GT (1) GT201300144A (es)
MA (1) MA34806B1 (es)
MX (1) MX2013006187A (es)
NZ (1) NZ610467A (es)
PE (1) PE20140792A1 (es)
PH (1) PH12013501098A1 (es)
RU (1) RU2013130224A (es)
SG (1) SG190210A1 (es)
TW (1) TW201304779A (es)
WO (1) WO2012075253A2 (es)
ZA (1) ZA201303223B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192367A1 (en) * 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
CN104661652B (zh) * 2012-09-27 2018-08-28 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
PT3560924T (pt) 2015-04-02 2021-07-02 Merck Patent Gmbh Imidazolinilquinolinas e a sua utilização como inibidores da cinase atm
KR20180058659A (ko) 2015-05-20 2018-06-01 노파르티스 아게 에베롤리무스와 닥톨리십의 약제학적 병용물
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
US20210346374A1 (en) * 2016-10-03 2021-11-11 Suven Life Sciences Limited Pharmaceutical compositions of 5-ht6 receptor antagonist
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
JP2022543803A (ja) * 2019-08-07 2022-10-14 アクリプス ワン インコーポレイテッド （６ａＳ）－６－メチル－５，６，６ａ，７－テトラヒドロ－４Ｈ－ジベンゾ［ｄｅ，ｇ］キノリン－１０，１１－ジオールの医薬組成物
DK4076404T3 (da) * 2019-12-20 2024-01-22 Intervet Int Bv Farmaceutisk pyrazolsammensætning

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AU2004295061B2 (en) * 2003-11-21 2008-11-20 Novartis Ag 1H-imidazoquinoline derivatives as protein kinase inhibitors
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20080125477A1 (en) * 2006-05-16 2008-05-29 Decode Genetics, Ehf. 7-(acryloyl) indole compositions and methods of making and using same
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
WO2008079629A2 (en) * 2006-12-21 2008-07-03 Boehringer Ingelheim International Gmbh Formulations with improved bioavailability
AU2008218806B2 (en) * 2007-02-20 2011-12-01 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors

Also Published As

Publication number Publication date
CA2817618A1 (en) 2012-06-07
AR084067A1 (es) 2013-04-17
JP2013544845A (ja) 2013-12-19
US20130245061A1 (en) 2013-09-19
MA34806B1 (fr) 2014-01-02
TW201304779A (zh) 2013-02-01
KR20140010009A (ko) 2014-01-23
GT201300144A (es) 2014-06-09
CN103237544A (zh) 2013-08-07
WO2012075253A3 (en) 2012-08-09
CL2013001557A1 (es) 2013-10-25
PH12013501098A1 (en) 2013-07-08
NZ610467A (en) 2015-01-30
SG190210A1 (en) 2013-06-28
EP2645999A2 (en) 2013-10-09
WO2012075253A2 (en) 2012-06-07
RU2013130224A (ru) 2015-01-10
MX2013006187A (es) 2013-07-15
ECSP13012654A (es) 2013-08-30
CO6801722A2 (es) 2013-11-29
ZA201303223B (en) 2014-01-29
AU2011336478A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
PE20140792A1 (es) Composiciones farmaceuticas
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
UY37998A (es) Agentes antivirales contra la hepatitis b
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
AR062282A1 (es) Composiciones colorantes
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20190111A1 (es) Nuevos derivados aminoacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
PE20191652A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
PE20080123A1 (es) Composiciones farmaceuticas que contienen vx-950 en el tratamiento de hepatitis c
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20200608A1 (es) Nuevos derivados de azaquinolina
AR076859A1 (es) Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR046959A1 (es) Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
AR082633A1 (es) Analogos de tetraciclina
UY38383A (es) Heterociclos funcionalizados como agentes antivirales

Legal Events

Date Code Title Description
FD Application declared void or lapsed